The spectrum of neurologic disease associated with anti-GM1 antibodies

S. A. Sadiq, F. P. Thomas, K. Kilidireas, S. Protopsaltis, A. P. Hays, K. W. Lee, S. N. Romas, N. Kumar, L. Den Van Berg, M. Santoro, D. J. Lange, D. S. Younger, R. E. Lovelace, W. Trojaborg, W. H. Sherman, J. R. Miller, J. Minuk, M. A. Fehr, R. I. Roelofs, D. Hollander & 6 others Fenwick T Nichols, H. Mitsumoto, J. J. Kelley, Thomas Robert Swift, T. L. Munsat, N. Latov

Research output: Contribution to journalArticle

249 Citations (Scopus)

Abstract

We compared anti-GM1 IgM antibody titers in patients with various neurologic diseases and in normal subjects. We found increased titers in patients with lower motor neuron disease, sensorimotor neuropathy, or motor neuropathy with or without multifocal conduction block. In patients with other diseases, titers are similar to those in normal individuals, suggesting that anti-GM1, antibody levels are not increased nonspecifically after neural injury or inflammatory diseases. Anti- GM1, antibodies in many of the patients occur as monoclonal gammopathies, predominantly of lambda light-chain type, but the antibodies are sometimes polyclonal with normal or increased serum IgM concentrations. Most of the anti-GM1, antibodies appear to react with the Gal(pl-3)GalNAc epitope which is shared with asialo-GM1, and GD1,b, but in some patients the antibodies are more specific for GM1, and associated with motor neuropathy. Patients with motor or sensorimotor peripheral neuropathy or lower motor neuron disease should be tested for anti-GM, antibodies or anti-Gal(pi-3)GalNAc antibodies, as therapeutic reduction in antibody concentrations was reported to result in clinical improvement in some patients.

Original languageEnglish (US)
Pages (from-to)1067-1072
Number of pages6
JournalNeurology
Volume40
Issue number7
StatePublished - Jan 1 1990

Fingerprint

Nervous System Diseases
Anti-Idiotypic Antibodies
Antibodies
Motor Neuron Disease
Paraproteinemias
Peripheral Nervous System Diseases
Immunoglobulin M
Epitopes
Light
Wounds and Injuries
Serum

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Sadiq, S. A., Thomas, F. P., Kilidireas, K., Protopsaltis, S., Hays, A. P., Lee, K. W., ... Latov, N. (1990). The spectrum of neurologic disease associated with anti-GM1 antibodies. Neurology, 40(7), 1067-1072.

The spectrum of neurologic disease associated with anti-GM1 antibodies. / Sadiq, S. A.; Thomas, F. P.; Kilidireas, K.; Protopsaltis, S.; Hays, A. P.; Lee, K. W.; Romas, S. N.; Kumar, N.; Van Berg, L. Den; Santoro, M.; Lange, D. J.; Younger, D. S.; Lovelace, R. E.; Trojaborg, W.; Sherman, W. H.; Miller, J. R.; Minuk, J.; Fehr, M. A.; Roelofs, R. I.; Hollander, D.; Nichols, Fenwick T; Mitsumoto, H.; Kelley, J. J.; Swift, Thomas Robert; Munsat, T. L.; Latov, N.

In: Neurology, Vol. 40, No. 7, 01.01.1990, p. 1067-1072.

Research output: Contribution to journalArticle

Sadiq, SA, Thomas, FP, Kilidireas, K, Protopsaltis, S, Hays, AP, Lee, KW, Romas, SN, Kumar, N, Van Berg, LD, Santoro, M, Lange, DJ, Younger, DS, Lovelace, RE, Trojaborg, W, Sherman, WH, Miller, JR, Minuk, J, Fehr, MA, Roelofs, RI, Hollander, D, Nichols, FT, Mitsumoto, H, Kelley, JJ, Swift, TR, Munsat, TL & Latov, N 1990, 'The spectrum of neurologic disease associated with anti-GM1 antibodies', Neurology, vol. 40, no. 7, pp. 1067-1072.
Sadiq SA, Thomas FP, Kilidireas K, Protopsaltis S, Hays AP, Lee KW et al. The spectrum of neurologic disease associated with anti-GM1 antibodies. Neurology. 1990 Jan 1;40(7):1067-1072.
Sadiq, S. A. ; Thomas, F. P. ; Kilidireas, K. ; Protopsaltis, S. ; Hays, A. P. ; Lee, K. W. ; Romas, S. N. ; Kumar, N. ; Van Berg, L. Den ; Santoro, M. ; Lange, D. J. ; Younger, D. S. ; Lovelace, R. E. ; Trojaborg, W. ; Sherman, W. H. ; Miller, J. R. ; Minuk, J. ; Fehr, M. A. ; Roelofs, R. I. ; Hollander, D. ; Nichols, Fenwick T ; Mitsumoto, H. ; Kelley, J. J. ; Swift, Thomas Robert ; Munsat, T. L. ; Latov, N. / The spectrum of neurologic disease associated with anti-GM1 antibodies. In: Neurology. 1990 ; Vol. 40, No. 7. pp. 1067-1072.
@article{678419ea594d4ab1b191eaced8b9bfbb,
title = "The spectrum of neurologic disease associated with anti-GM1 antibodies",
abstract = "We compared anti-GM1 IgM antibody titers in patients with various neurologic diseases and in normal subjects. We found increased titers in patients with lower motor neuron disease, sensorimotor neuropathy, or motor neuropathy with or without multifocal conduction block. In patients with other diseases, titers are similar to those in normal individuals, suggesting that anti-GM1, antibody levels are not increased nonspecifically after neural injury or inflammatory diseases. Anti- GM1, antibodies in many of the patients occur as monoclonal gammopathies, predominantly of lambda light-chain type, but the antibodies are sometimes polyclonal with normal or increased serum IgM concentrations. Most of the anti-GM1, antibodies appear to react with the Gal(pl-3)GalNAc epitope which is shared with asialo-GM1, and GD1,b, but in some patients the antibodies are more specific for GM1, and associated with motor neuropathy. Patients with motor or sensorimotor peripheral neuropathy or lower motor neuron disease should be tested for anti-GM, antibodies or anti-Gal(pi-3)GalNAc antibodies, as therapeutic reduction in antibody concentrations was reported to result in clinical improvement in some patients.",
author = "Sadiq, {S. A.} and Thomas, {F. P.} and K. Kilidireas and S. Protopsaltis and Hays, {A. P.} and Lee, {K. W.} and Romas, {S. N.} and N. Kumar and {Van Berg}, {L. Den} and M. Santoro and Lange, {D. J.} and Younger, {D. S.} and Lovelace, {R. E.} and W. Trojaborg and Sherman, {W. H.} and Miller, {J. R.} and J. Minuk and Fehr, {M. A.} and Roelofs, {R. I.} and D. Hollander and Nichols, {Fenwick T} and H. Mitsumoto and Kelley, {J. J.} and Swift, {Thomas Robert} and Munsat, {T. L.} and N. Latov",
year = "1990",
month = "1",
day = "1",
language = "English (US)",
volume = "40",
pages = "1067--1072",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - The spectrum of neurologic disease associated with anti-GM1 antibodies

AU - Sadiq, S. A.

AU - Thomas, F. P.

AU - Kilidireas, K.

AU - Protopsaltis, S.

AU - Hays, A. P.

AU - Lee, K. W.

AU - Romas, S. N.

AU - Kumar, N.

AU - Van Berg, L. Den

AU - Santoro, M.

AU - Lange, D. J.

AU - Younger, D. S.

AU - Lovelace, R. E.

AU - Trojaborg, W.

AU - Sherman, W. H.

AU - Miller, J. R.

AU - Minuk, J.

AU - Fehr, M. A.

AU - Roelofs, R. I.

AU - Hollander, D.

AU - Nichols, Fenwick T

AU - Mitsumoto, H.

AU - Kelley, J. J.

AU - Swift, Thomas Robert

AU - Munsat, T. L.

AU - Latov, N.

PY - 1990/1/1

Y1 - 1990/1/1

N2 - We compared anti-GM1 IgM antibody titers in patients with various neurologic diseases and in normal subjects. We found increased titers in patients with lower motor neuron disease, sensorimotor neuropathy, or motor neuropathy with or without multifocal conduction block. In patients with other diseases, titers are similar to those in normal individuals, suggesting that anti-GM1, antibody levels are not increased nonspecifically after neural injury or inflammatory diseases. Anti- GM1, antibodies in many of the patients occur as monoclonal gammopathies, predominantly of lambda light-chain type, but the antibodies are sometimes polyclonal with normal or increased serum IgM concentrations. Most of the anti-GM1, antibodies appear to react with the Gal(pl-3)GalNAc epitope which is shared with asialo-GM1, and GD1,b, but in some patients the antibodies are more specific for GM1, and associated with motor neuropathy. Patients with motor or sensorimotor peripheral neuropathy or lower motor neuron disease should be tested for anti-GM, antibodies or anti-Gal(pi-3)GalNAc antibodies, as therapeutic reduction in antibody concentrations was reported to result in clinical improvement in some patients.

AB - We compared anti-GM1 IgM antibody titers in patients with various neurologic diseases and in normal subjects. We found increased titers in patients with lower motor neuron disease, sensorimotor neuropathy, or motor neuropathy with or without multifocal conduction block. In patients with other diseases, titers are similar to those in normal individuals, suggesting that anti-GM1, antibody levels are not increased nonspecifically after neural injury or inflammatory diseases. Anti- GM1, antibodies in many of the patients occur as monoclonal gammopathies, predominantly of lambda light-chain type, but the antibodies are sometimes polyclonal with normal or increased serum IgM concentrations. Most of the anti-GM1, antibodies appear to react with the Gal(pl-3)GalNAc epitope which is shared with asialo-GM1, and GD1,b, but in some patients the antibodies are more specific for GM1, and associated with motor neuropathy. Patients with motor or sensorimotor peripheral neuropathy or lower motor neuron disease should be tested for anti-GM, antibodies or anti-Gal(pi-3)GalNAc antibodies, as therapeutic reduction in antibody concentrations was reported to result in clinical improvement in some patients.

UR - http://www.scopus.com/inward/record.url?scp=0025371989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025371989&partnerID=8YFLogxK

M3 - Article

VL - 40

SP - 1067

EP - 1072

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 7

ER -